Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of the macrophage activation syndrome: Re-analysis of a prior Phase III trial

OBJECTIVE: To determine the efficacy of anakinra (recombinant interleukin-1 receptor antagonist) in improving 28-day survival in sepsis patients with features of macrophage activation syndrome (MAS). Despite equivocal results in sepsis trials, anakinra is effective in treating MAS, a similar entity...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Crit Care Med
Main Authors: Shakoory, B., Carcillo, J.A., Chatham, W. W., Amdur, R. L., Zhao, H., Dinarello, C.A., Cron, R.Q., Opal, S.M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5378312/
https://ncbi.nlm.nih.gov/pubmed/26584195
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CCM.0000000000001402
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados